DOCSLIB.ORG

CER 225: Interventions for Substance Use Disorders in Adolescents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CER 225: Interventions for Substance Use Disorders in Adolescents Comparative Effectiveness Review Number 225 R Interventions for Substance Use Disorders in Adolescents: A Systematic Review Comparative Effectiveness Review Number 225 Interventions for Substance Use Disorders in Adolescents: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00002-I Prepared by: Brown Evidence-based Practice Center Providence, RI Investigators: Dale W. Steele, M.D., M.Sc. Sara J. Becker, Ph.D. Kristin J. Danko, Ph.D. Ethan M. Balk, M.D., M.P.H. Ian J. Saldanha, M.B.B.S., M.P.H., Ph.D. Gaelen P. Adam, M.L.I.S., M.P.H. Sarah M. Bagley, M.D., M.Sc. Catherine Friedman, M.D. Anthony Spirito, M.D. Kelli Scott, Ph.D. Evangelia E. Ntzani, M.D. Iman Saeed, Sc.M. Bryant Smith, M.S., C.P.H. Jonah Popp. Ph.D. Thomas A. Trikalinos, M.D., Ph.D. AHRQ Publication No. 20-EHC014 May 2020 This report is based on research conducted by the Brown Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00002-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. The information in this report is intended to help health care decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders. AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies may not be stated or implied. This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report. AHRQ appreciates appropriate acknowledgment and citation of its work. Suggested language for acknowledgment: This work was based on an evidence report, [INSERT TITLE], by the Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality (AHRQ). Suggested citation: Steele DW, Becker SJ, Danko KJ, Balk EM, Saldanha IJ, Adam GP, Bagley SM, Friedman C, Spirito A, Scott K, Ntzani EE, Saeed I, Smith B, Popp J, Trikalinos TA. Interventions for Substance Use Disorders in Adolescents: A Systematic Review. Comparative Effectiveness Review No. 225. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2015-00002-I.) AHRQ Publication No. 20-EHC014. Rockville, MD: Agency for Healthcare Research and Quality. May 2020. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org/10.23970/AHRQEPCCER225. ii Preface The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies. Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see https://effectivehealthcare.ahrq.gov/about/epc/evidence-synthesis. AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an e- mail list to learn about new program products and opportunities for input. If you have comments on this systematic review, they may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, or by email to [email protected]. Gopal Khanna, M.B.A. Arlene Bierman, M.D., M.S. Director Director Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality Stephanie Chang, M.D., M.P.H. Suchitra Iyer, Ph.D. Director Task Order Officer Evidence-based Practice Center Program Center for Evidence and Practice Center for Evidence and Practice Improvement Improvement Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality iii Acknowledgments The authors gratefully acknowledge the following individuals for their contributions to this project: Jenni Quiroz, B.S., Khamden Soch, M.S., and Anya Wallack, Ph.D. Key Informants In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants. Key Informants must disclose any financial conflicts of interest greater than $5,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest. The list of Key Informants who provided input to this report follows: David “Joel” Beckstead, Ph.D. Indian Health Service (IHS) Sharon Levy, M.D., M.P.H.* † Rockville, MD Boston Children's Hospital Boston, MA Kirsten Beronio, J.D. The Center for Medicaid and CHIP Services Frederick Muench, Ph.D. Washington, DC Center on Addiction Kevin M. Gray, M.D.* † New York, NY Medical University of South Carolina Charleston, SC Ruth Potee, M.D. Valley Medical Group Aaron Hogue, Ph.D.* † Greenfield, MA Center on Addiction New York, NY Sheryl Ryan, M.D.* † Penn State Children’s Hospital Danica Kalling Knight, Ph.D. Hershey, PA Texas Christian University Fort Worth, TX Audra Stock, L.P.C., MAC Ellen Kreida, M.P.H., L.I.C.S.W. Substance Abuse and Mental Health MA Department of Children and Families Services Administration (SAMHSA) Boston, MA Rockville, MD Justine Larson, M.D., M.P.H., M.H.S.* † Geetha Subramaniam, M.D. The Substance Abuse and Mental Health National Institute on Drug Abuse (NIDA) Services Administration (SAMHSA) Rockville, MD Rockville, MD iv * Also Peer Reviewer † Also Technical Expert Panel member Technical Expert Panel In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts. Technical Experts must disclose any financial conflicts of interest greater than $5,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified. The list of Technical Experts who provided input to this report follows: Craig Henderson, Ph.D.* Sam Houston State University Huntsville, TX Emily Tanner-Smith, Ph.D.* University of Oregon Eugene, OR * Also Peer Reviewer Peer Reviewers Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report does not necessarily represent the views of individual reviewers. Peer Reviewers must disclose any financial conflicts of interest greater than $5,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified. The list of Peer Reviewers follows: Rongwei (Rochelle) Fu, Ph.D.
Load more

Recommended publications
  • 1,4-Benzodiazepine: an Overview of Biological Properties
    Sci. Revs. Chem. Commun.: 5(1), 2015, 13-20 ISSN 2277-2669 1,4-BENZODIAZEPINE: AN OVERVIEW OF BIOLOGICAL PROPERTIES IRAM KHAN*, ANUPAMA and BHAWANI SINGHa Department of Chemistry, Banasthali University, BANASTHALI (Raj.) INDIA aDepartment of Pure & Applied Chemistry, University of Kota, KOTA (Raj.) INDIA (Received : 16.02.2015; Accepted : 02.03.2015) ABSTRACT The term benzodiazepine is the chemical name for the heterocyclic ring system, which is a fusion of benzene and diazepine ring systems. 1,4-benzodiazepine is related with a huge range of biological properties. These ring systems are incorporated into drugs used for AIDS, cancer, anti-viral treatment etc. 1,4-benzodiazepine derivatives are well established in the literature as important biologically active compounds. They have a long history of application in agrochemicals and pharmaceutical industry as herbicides and active pharmaceuticals. 1,4-benzodiazepine and their numerous derivatives have continued to capture the concentration of chemists since their existence in the biologically active materials have been known to produce additive effect on the bio-efficacy of the molecules. Key words: 1,4-benzodiazepine, anti-viral, bio-efficacy. INTRODUCTION History of benzodiazepines was started after the discovery of diazepam (Fig. 1) in 1955 by Leo Sternbach. From that day the research on 1,4- benzodiazepine nucleus is continue. There is a lots of drugs having 1,4-benzodiazepine nucleus. 1,4-Benzodiazepine nucleus containing drugs mostly used for the treatment of anxiety, but they also are useful in treating several other conditions in human. It is a most common prescribed drug for CNS disorders. Benzodiazepines affect a neurotransmitter chemical, gamma- aminobutyric acid (GABA), which is used by nerves to communicate with one another1.
    [Show full text]
  • Treatments for Spasticity and Pain in Multiple Sclerosis: a Systematic Review
    This is a repository copy of Treatments for spasticity and pain in multiple sclerosis: a systematic review . White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/1776/ Monograph: Beard, S.M., Hunn, A. and Wight, J. (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Technical Report. Gray Publishing , Tunbridge Wells. ISSN 1366-5278 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Health Technology Assessment 2003; Vol. 7: No. 40 Treatments for spasticity and pain in multiple sclerosis: a systematic review S Beard A Hunn J Wight Health Technology Assessment NHS R&D HTA Programme HTA HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.ncchta.org).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Touchpoints for Addressing Substance Use Issues in Home Visiting: Phase 1 Final Report OPRE Report 2020-27 March 2020
    Anchor Touchpoints for Addressing Substance Use Issues in Home Visiting: Phase 1 Final Report OPRE Report 2020-27 March 2020 This page has been left blank for double-sided copying. Touchpoints for Addressing Substance Use Issues in Home Visiting: Phase 1 Final Report OPRE Report 2020-27 March 2020 Mynti Hossain, Lauren Akers, Patricia Del Grosso, Marisa Shenk, Michael Cavanaugh, and Melissa Azur Submitted to: Nicole Denmark, Project Officer Office of Planning, Research, and Evaluation Administration for Children and Families U.S. Department of Health and Human Services Contract Number: HHSP233201500035I Submitted by: Mathematica P.O. Box 2393 Princeton, NJ 08543-2393 Telephone: (609) 799-3535 Project Director: Patricia Del Grosso This report is in the public domain. Permission to reproduce is not necessary. Suggested citation: Hossain, Mynti, Akers, Lauren, Del Grosso, Patricia, Shenk, Marisa, Cavanaugh, Michael, and Azur, Melissa (2020). Touchpoints for Addressing Substance Use Issues in Home Visiting: Phase 1 Final Report, OPRE Report # 2020-27. Washington, DC: Office of Planning, Research, and Evaluation, Administration for Children and Families, U.S. Department of Health and Human Services. Disclaimer: The views expressed in this publication do not necessarily reflect the views or policies of the Office of Planning, Research, and Evaluation, the Administration for Children and Families, or the U.S. Department of Health and Human Services. This report and other reports sponsored by the Office of Planning, Research, and Evaluation are available at http://www.acf.hhs.gov/opre. Sign-up for the OPRE Newsletter Follow OPRE on Like OPRE on Facebook Follow OPRE on Twitter @OPRE_ACF facebook.com/OPRE.ACF Instagram@opre_acf This page has been left blank for double-sided copying.
    [Show full text]
  • Outcome Measurements in Economic Evaluations of Drug Misuse Interventions
    Outcome Measurements in Economic Evaluations of Drug Misuse Interventions Ching-Wen Chang A thesis submitted as fulfilment for the degree of Doctor of Philosophy Department of Health Sciences University of York September 2010 To my grandfather 2 Abstract This thesis critically evaluates the measurement of outcomes in economic evaluations of drug misuse interventions. Three different aspects of measuring outcomes are examined: one focusing on non-monetary outcomes at the individual patient level; one focusing on monetary outcomes within studies using individual patient level data; and one focusing on long-term outcomes, both monetary and non-monetary. The many limitations of measuring these outcomes in existing economic evaluations of drug misuse interventions are exposed and the problems with conducting such studies are identified. The importance of this thesis is thus in providing an overview and methodological critique of the extant economic evaluations of drug misuse interventions. In addition a decision analytic model for a drug testing in schools programme is developed to illustrate how the limitations highlighted in the methodological critique might be addressed by future research. The findings of the thesis reveal the problems with using EQ-5D as a generic outcome measure for economic evaluations of drug misuse interventions, as is recommended by NICE in the UK. The nature of drug misuse problems requires that a wide range of different measures, including drug misuse specific measures, must be taken into account when evaluating drug misuse interventions. Similarly, the limitations with existing studies that attempt to estimate the monetary outcome of drug misuse interventions are exposed, as many studies fail to take into account all of the costs that will determine the monetary impact of an intervention for society.
    [Show full text]
  • Cannabis and Psychosis: a Critical Overview of the Relationship
    Curr Psychiatry Rep (2016) 18:12 DOI 10.1007/s11920-015-0657-y SUBSTANCE USE AND RELATED DISORDERS (F LEVIN AND E DAKWAR, SECTION EDITORS) Cannabis and Psychosis: a Critical Overview of the Relationship 1 2,3,4,5 Charles Ksir & Carl L. Hart # Springer Science+Business Media New York 2016 Abstract Interest in the relationship between cannabis use examination, along with a variety of other problem behaviors and psychosis has increased dramatically in recent years, in (e.g., early or heavy use of cigarettes or alcohol and poor part because of concerns related to the growing availability of school performance). Future research studies that focus exclu- cannabis and potential risks to health and human functioning. sively on the cannabis-psychosis association will therefore be There now exists a plethora of scientific articles addressing of little value in our quest to better understand psychosis and this issue, but few provide a clear verdict about the causal how and why it occurs. nature of the cannabis-psychosis association. Here, we review recent research reports on cannabis and psychosis, giving par- Keywords Marijuana . Schizophrenia . Mental illness . ticular attention to how each report provides evidence relating Cognition . THC . Psychotic disorder to two hypotheses: (1) cannabis as a contributing cause and (2) shared vulnerability. Two primary kinds of data are brought to bear on this issue: studies done with schizophrenic patients Introduction and studies of first-episode psychosis. Evidence reviewed here suggests that cannabis does not in itself cause a psychosis There has been a recent explosion of interest in the relationship disorder. Rather, the evidence leads us to conclude that both between cannabis use and psychosis, with over 100 papers ad- early use and heavy use of cannabis are more likely in indi- dressing this topic each year since 2012, compared to fewer than viduals with a vulnerability to psychosis.
    [Show full text]
  • Mental Disorders and Illicit Drug Use Expert Group
    Global Burden of Disease Mental Disorders and Illicit Drug Use Expert Group Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey Benzodiazepine-related mortality Illicit Drugs Discussion Paper No. 1 GBD2005 Mental Disorders and Illicit Drug Use Expert Group www.gbd.unsw.edu.au BENZODIAZEPINE-RELATED MORTALITY Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey Illicit Drugs Discussion Paper No. 1 Recommended citation: Charlson, F., Degenhardt, L., McLaren, J., Hall, W., & Lynskey, M. (2008). Benzodiazepine- related mortality. Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group, Illicit drugs discussion paper No. 1. National Drug and Alcohol Research Centre, University of NSW: Sydney. ISBN: 978 0 7334 2688 9 ©NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2008 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney,NSW 2052, Australia. GBD2005 Mental Disorders and Illicit Drug Use Expert Group www.gbd.unsw.edu.au Table of contents Summary and recommendations .............................................................................................. 1 1. Introduction
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Correlations and Agreement Between Delta9tetrahydrocannabinol (THC
    bs_bs_banner RESEARCH REPORT doi:10.1111/j.1360-0443.2011.03757.x Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trialadd_3757 1123..1131 Carsten Rygaard Hjorthøj1, Allan Fohlmann1, Anne-Mette Larsen1, Mikkel Arendt2 & Merete Nordentoft1 Mental Health Centre Copenhagen and Faculty of Health Sciences, University of Copenhagen, Copenhagen NV, Denmark1 and Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aarhus University Hospital, Aalborg, Denmark2 ABSTRACT Aims To assess correlations and agreement between timeline follow-back (TLFB)-assisted self-report and blood samples for cannabis use. Design Secondary analysis of a randomized trial. Setting Copenhagen, Denmark. Participants One hundred and three patients from the CapOpus trial with cannabis use disorder and psychosis, providing 239 self-reports of cannabis use and 88 valid blood samples. Measurements Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-delta-9-tetrahydrocannabinol-9- carboxylic acid (THC-COOH) detected in plasma using high-performance liquid chromatography with tandem mass spectrometry detection. Self-report of cannabis-use last month by TLFB. Pearson’s r, sensitivity and specificity calcu- lated as measures of correlation or agreement. Findings Correlations were strong; r = 0.75 for number of days and r = 0.83 for number of standard joints in the preceding month when excluding outliers. Including outliers, coefficients were moderate to strong (r = 0.49). There were differences in subgroups, mainly inconsistent, depending on inclusion or exclusion of outliers.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Ling Af Mennesker Med Skizofreni Og Komplekse Behand- Lingsforløb Vedvarende Symptomer, Mis- Brug Eller Mangelfuld Behand- Lingstilknytning
    National Klinisk Ret- ningslinje for behand- ling af mennesker med skizofreni og komplekse behand- lingsforløb Vedvarende symptomer, mis- brug eller mangelfuld behand- lingstilknytning Titel National Klinisk Retningslinje for behandling af mennesker med skizofreni - vedva- rende symptomer, misbrug eller mangelfuld behandlingstilknytning © Sundhedsstyrelsen, år. Publikationen kan frit refereres med tydelig kildeangivelse. Sundhedsstyrelsen Axel Heides Gade 1 2300 København S URL: http://www.sst.dk Sprog: Dansk Kategori: Faglig rådgivning. Høringsversion: 23. februar 2015. Format: PDF 2 / 131 Indhold 1 Indledning 8 1.1 Formål 8 1.2 Afgrænsning af patientgruppe 8 1.3 Målgruppe/brugere 8 1.4 Emneafgrænsning 8 1.5 Patientperspektivet 10 1.6 Juridiske forhold 10 2 Farmakologisk behandling 11 2.1 Reduktion af clozapin-dosis ved plasmakoncentration over den øvre grænse i det orienterende terapeutiske interval (fokuseret spørgsmål 1) 11 2.1.1 Anbefaling 11 2.1.2 Praktiske råd og særlige patientovervejelser 11 2.1.3 Baggrund for valg af spørgsmål 11 2.1.4 Litteratur 12 2.1.5 Gennemgang af evidensen 12 2.1.6 Arbejdsgruppens overvejelser 12 2.1.7 Rationale for anbefaling 13 2.2 Depotbehandling med antipsykotika (fokuseret spørgsmål 2) 14 2.2.1 Anbefaling 14 2.2.2 Praktiske råd og særlige patientovervejelser 14 2.2.3 Baggrund for valg af spørgsmål 14 2.2.4 Litteratur 15 2.2.5 Gennemgang af evidensen 15 2.2.6 Summary of Findings-tabel 16 2.2.7 Arbejdsgruppens overvejelser 19 2.2.8 Rationale for anbefaling 19 2.3 Tillægsbehandling med SSRI/SNRI (fokuseret
    [Show full text]
  • This Is the Author's Version of a Work That Was Submitted
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Queensland University of Technology ePrints Archive This is the author’s version of a work that was submitted/accepted for pub- lication in the following source: Rebgetz, Shane, Kavanagh, David J.,& Hides, Leanne (2016) Changes in cannabis use among psychotic clients without specialised sub- stance use treatment. Schizophrenia Research, 175(1-3), pp. 136-141. This file was downloaded from: https://eprints.qut.edu.au/94460/ c Crown Copyright c 2016 Published by Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 Notice: Changes introduced as a result of publishing processes such as copy-editing and formatting may not be reflected in this document. For a definitive version of this work, please refer to the published source: https://doi.org/10.1016/j.schres.2016.03.030 1 This is the preprint version of the journal article accepted for publication. Please cite as: Rebgetz, S., Kavanagh, D. J. Hides, L. Changes in cannabis use among psychotic clients without specialised substance use treatment, Schizophrenia Research, doi: 10.1016/j.schres.2016.03.030. 2 Corresponding Author: Mr Shane Rebgetz Locked Mail Bag 3 Caboolture Queensland Australia 4510 T: +61 7 5316 3100 (Australia) F: +61 7 5499 3171 (Australia) E-Mail: [email protected] Original article Changes in cannabis use among psychotic clients without specialised substance use treatment Shane Rebgetz1,2, David J Kavanagh1, Leanne Hides1 Authors: 1 Institute of Health & Biomedical Innovation and School of Psychology & Counselling, Queensland University of Technology, Brisbane, QLD, Australia.
    [Show full text]